Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice

• Main Authors: Dan Zhang (Author), Shanzhuang Niu (Author), Yicheng Ma (Author), Hang Chen (Author), Yu Wen (Author), Mingke Li (Author), Bo Zhou (Author), Yi Deng (Author), Chunjing Shi (Author), Guangyu Pu (Author), Meng Yang (Author), Xianmei Wang (Author), Chenggang Zou (Author), Yuanli Chen (Author), Lanqing Ma (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Fenofibrate is widely used in clinical therapy to effectively ameliorate the development of non-alcoholic fatty liver disease (NAFLD); however, its specific molecular mechanism of action remains largely unknown. MicroRNAs (miRNAs) are key mediators in regulating endoplasmic reticulum (ER) stress dur...